ArticleBMC nephrology2026
CD71
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The mechanism of anemia in patients with end-stage renal disease (ESRD) and its association with poor prognoses (including cardiovascular disease and mortality) are unclear. We investigated the role of CD71+ erythroid progenitor cells (EPCs), which are associated with compensatory extramedullary hematopoiesis in anemia and cancers, in patients and mice with ESRD. Circulatory CD45−EPCs (CD45−CD71+CD235a+) were elevated in patients with ESRD and 5/6th partial nephrectomy (PNx) mice compared with those in healthy controls. CD45+EPCs (CD45+CD71+CD235a+) in peripheral blood mononuclear cells (PBMCs) were elevated in patients with ESRD. CD45+EPCs were positively associated with hemoglobin levels, whereas CD45−EPCs were negatively associated. Wright–Giemsa staining revealed that the majority of CD45−EPCs were mainly anucleated red blood cells, many of which were ruptured, and CD45+EPCs exhibited multiple stages of erythroblasts and ruptured cells. Single-cell RNA sequencing of CD45+EPCs revealed that CD45⁺ EPC population exhibits a mixed transcriptional signature with features of both erythroid and myeloid lineages. CD45+EPCs in patients with ESRD exhibited increased myeloid cell surface markers, decreased maturation potential, as well as mitochondrial retention and dysfunction. CD71+EPCs in PNx mice promoted tumor metastasis associated with platelets. Pathological analysis and immunofluorescence revealed that CD71+EPC were mainly located in the arterial subintima, and their abundance was positively associated with the pathological grading of atherosclerosis. Kaplan–Meier and multivariate Cox analyses revealed that patients with high levels of CD45−EPCs presented an increased incidence of stroke. Overall, accumulation of CD71+EPCs were invalid extramedullary hematopoiesis compensation in ESRD and mediates anemia-related poor prognoses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.